| Media Room :: Press Releases :: Nymox's NicAlert™ Used in Conjunction With Nicotine Replacement Therapy Results in Higher Smoking Cessation Success Rates

search the site...

Company Info		Media Room		Financial Info		Research		Products

Fact Sheet		Press Releases

		20030522 < articles < press << main


Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times Nymox Updates NX-1207 Product Development Activities Nymox NX-1207 Data Presented Today at American Urological Association Meeting in Chicago Clinical Results for Nymox BPH Drug NX-1207 to Be Presented at American Urological Association Meeting in Chicago on September 25 Nymox NX-1207 Data Presented at American Urological Association Meetings in San Diego and Santa Ana Pueblo, New Mexico Clinical Trial Results for NX-1207 to be Presented at Second AUA Meeting in San Diego on September 18 Clinical Trial Investigators To Present New Data Next Week on Nymox’s NX-1207 For Benign Prostatic Hyperplasia Nymox Reports Second Quarter 2008 Financial Results New Long-Term Prospective Study of Statin Drugs Confirms Utility To Reduce Risk of Dementia and Memory Loss New Data on Nymox BPH Drug To Be Presented at American Urological Association Meeting in Monterey October 26-30 Nymox’s NicAlert™ Gains Acceptance in Clinical Trials and Research Studies Almost 50% of Americans Exposed to Second-Hand Smoke According to New Report From Centers for Disease Control BPH: A Major Challenge for Men’s Healthcare - Nymox's Innovative Treatment for BPH Enters Phase 3 Independent Clinical Trial Investigators To Present New Data on Nymox’s NX-1207 Drug in Development For Benign Prostatic Hyperplasia Nymox Starts Phase 3 Program for NX-1207 Nymox Announces New Clinical Trial Data Presentation on BPH Drug at Upcoming American Urological Association Meeting Nymox Reports Significant Long-Term Improvement in BPH Symptoms After NX-1207 Treatment in New Multi-Center U.S. Study Independent Clinical Investigators to Present Data on Nymox BPH Drug at American Urological Association Meeting in Chicago September 25 Nymox Reports First Quarter 2008 Financial Results Nymox Reports New Large Cohort U.S. 3 Year Follow-Up Clinical Study of NX-1207 for BPH Near Completion Brief Exposure to Second-Hand Smoke Bad for Health According to New Study Nymox Announces New Positive Results at 54 Months in Long Term Study of NX-1207 for Benign Prostatic Hyperplasia New Peer Review Publications Support Nymox Saliva Smoking Test Nymox Announces Clinical Study Presentation on BPH Drug at American Urological Association Meeting Nymox Nears Completion of Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Nymox Releases Positive New Clinical Trial Data on Response Rates to Company’s Prostate Drug NX-1207 Nymox Reports 2007 Financial Results Nymox Releases Further Results from Latest U.S. Study of NX-1207 for Benign Prostatic Hyperplasia Nymox’s NX-1207 Offers a New and Attractive Approach to the Treatment of Benign Prostatic Hyperplasia Two New Published Studies Emphasize The Need for Testing Tobacco Use and Second-Hand Smoke Exposure Nymox Pharmaceutical to Present at the Growth and Value Investor Conference Nymox Announces Positive Results from New Multi-Center U.S. Study of NX-1207 For BPH Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH Nymox Announces $15 Million Equity Financing Commitment Expert Review of Molecular Diagnostics Publishes Positive Report on Nymox Alzheimer Test Nymox Reports Update on NX-1207 Study Results, Marketing Plans and Activities Nymox Announces Positive Results in New 2 Year Blinded, Placebo Controlled Study of NX-1207 for Benign Prostatic Hyperplasia Nymox Reports Completion of Large New 2 Year Follow-up Study of Nymox Reports Third Quarter Financial Results for 2007 Nymox Announces Clinical Study Presentation on New BPH Drug at Upcoming American Urological Association Meeting Nymox Announces New BPH Drug Long Term Follow-up Study Clinical Data Presentation October 20 at American Urological Nymox Announces BPH Drug Clinical Data Presentation September 28 at American Urological Association Meeting Nymox Saliva Test Strongly Supported By New Independent Study Data Published in Cancer Epidemiology Biomarkers & Prevention Nymox BPH Drug Data Presentation September 8 at American Urological Association Meeting Major New Study Supports Validity of Statin Drugs Potential For Alzheimer’s Treatment Nymox Announces New Clinical Data From BPH Drug Trials To Be Presented at Upcoming U.S. Urology Meeting Nymox Reports Second Quarter Financial Results for 2007 WallStreet Research Releases Buy Recommendation for Nymox Pharmaceutical Corporation Nymox Announces New Drug Data to Be Presented at Upcoming U.S. Urology Meeting Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings NicAlert™ Study in Children to be Presented at American Thoracic Society Conference in San Francisco Nymox Reports First Quarter 2007 Financial Results Nymox Announces New Positive Results from 3 ½ Year Study of NX-1207 for Benign Prostatic Hyperplasia Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH Nymox Announces Positive Results from Newly Completed Long-Term Study of NX-1207 for Benign Prostatic Hyperplasia Nymox Reports 2006 Financial Results Nymox Reports Completion of New Long-term Study of NX-1207 for BPH Nymox Reports Update on Prostate Drug Licensing Negotiations Journal of Clinical Laboratory Analysis Publishes Positive New Data Bolstering Nymox’s AlzheimAlert™ Urine Test for Alzheimer’s Disease Nymox Protein Biomarker for Alzheimer's is Years Ahead of Competition Nymox NXC-4720 Reduces E. Coli Contamination By 99% Nymox Announces $13 Million Equity Financing Newly Published Editorial in Expert Opinion on Investigational Drugs Says Statins May Be Good for Alzheimer's Disease Nymox Pursuing New Approaches to an Old Disease Nymox Product a Tool for Smoking Cessation Efforts Nymox Reports Third Quarter 2006 Financial Results Statin Drugs Gain Traction as Potential Treatment for Alzheimer’s Disease Nymox Pharmaceutical to Present at the 29th Annual Westergaard SmallCap Conference Nymox Pursuing Plans for Marketing Partnerships for Its NX-1207 BPH Drug Demand for Enlarged Prostate Treatments Expected to Rise Sharply Journal of the American Medical Directors Association Publishes Positive Independent National Study of Nymox's AlzheimAlert™ Urine Test For Alzheimer's Disease Nymox Targets E. Coli Food Contamination with Innovative New Products Nymox Pharmaceutical to Present at the Noble Financial Small Cap Conference Nymox Announces Positive Results from Completed Phase 2 BPH Drug Trial Nymox Products Profiled in New Reports Nymox AlzheimAlert™ Independent Clinical Trial Data To Be Presented at the XXVIIIth International Congress of Clinical Neurophysiology New Lancet Study: Second Hand Smoke Increases Heart Attack Risk Nymox Reports Second Quarter 2006 Financial Results Second Hand Smoke Exposure Associated With Pediatric Anesthesia-Related Airway Complications Multiple Newly Published U.S. and European Peer-Review Studies Support Statin Drug Potential Therapeutic Use in Alzheimer's Disease Value of Nymox's NicAlert™ For Monitoring Pregnant Women Confirmed by New Independent Study in Alaska New Studies Bolster Potential of Statin Drugs for the Treatment of Alzheimer's Disease Nymox NicAlert™ Product to be Used in Large Collaboration For Smoking Cessation in U.K. Three Independent Analyst Reports Give Nymox “Buy” Recommendations New Study Proves Second Hand Smoke Makes Allergies Worse New Study Finds that Statin Drugs Protect Against Cognitive Decline New Buy Recommendation for Nymox in Report From WallStreet Research U.S. Survey: Enlarged Prostate Problems Pose a Major Challenge to Health Care Systems Nymox “Buy” Recommendations in Two Independent Analyst Reports New Nymox Product Study Data to be Presented at 13th World Conference on Tobacco or Health Surgeon General Declares Second-Hand Smoke Indisputable and Alarming Public Health Hazard Nymox Reports Update on Multi-Center Trial of Benign Prostatic Hyperplasia Drug U.S. and European Studies Support Statin Drug Mechanism For Potential Therapeutic Use in Alzheimer's Disease Nymox Signs New Sales and Marketing Agreement for Alzheimer's Test with Kyung Min Meditech Co. Ltd. In Korea Nymox Reports Completion of NX-1207 Dosing in Current Multi-Center BPH Drug Trial Nymox Pharmaceutical Corporation Holds Annual Shareholders Meeting New Study Links Second-Hand Smoke to Allergy Risk for Infants Updated Analyst Reports Give Nymox “Buy” Recommendation Nymox AlzheimAlert™ Findings To Be Presented at the XXVIIIth International Congress of Clinical Neurophysiology Nymox Reports Positive New Efficacy Data for Benign Prostatic Hyperplasia Drug Nymox Reports First Quarter 2006 Financial Results New Study of Infants Highlights Second Hand Smoke Risk Nymox AlzheimAlert™ Findings To Be Presented at the 4th Bologna International Meeting on Affective, Behavioral and Cognitive Disorders in the Elderly Nymox Gains Regulatory Milestone in Europe For Saliva Test Nymox Signs Italian Distribution Deal for NicAlert™ with Alifax S.p.A. Nymox's Second-Hand Smoke Test Newly Launched in the U.K. Nymox AlzheimAlert™ Findings To Be Presented at Annual Meeting of the American Psychiatric Association Long Term Statin Drug Use Safe According to Safety Task Force Nymox “Buy” Recommendations in Three Independent Analyst Reports Nymox Reports Latest Interim Review of Safety Data for Benign Prostatic Hyperplasia Drug Nymox to Present at Dutton Associates' “Recognizing Opportunity” SmallCap Conference in San Francisco March 28 Nymox Reports 2005 Financial Results; Product Sales Increase by 32% Nymox AlzheimAlert™ Findings To Be Presented at National Meeting in Dallas Nymox Expands Its Patent Portfolio Foundation For Product Development Nymox Study Data to be Presented at World Conference on Tobacco in Washington Nymox NXC-4720 Late Stage Product Targets E. Coli Food Contamination Statin Drug Potential for Alzheimer's Disease Gains Ground with Recent Studies Public Awareness of Health Risks from Second-Hand Smoke Exposure Grows Worldwide Nymox “Buy” Recommendations in Three Independent Analyst Reports Nymox Reports on Company's New Interim Review of Safety Data for Benign Prostatic Hyperplasia Drug What is Good for the Heart is Good for the Brain According to NIH Report Nymox Saliva Test Data to be Presented at National Meeting This Week Nymox AlzheimAlert™ Findings To Be Presented at Annual Meeting of the American Psychiatric Association Nymox's Alzheimer Test to be Provided in U.K. by Lab21 Statin Drug Potential for Alzheimer's Disease Bolstered by Recent Studies Nymox's Alzheimer Drug Programs Generate Several Novel Product Developments Nymox Recommended in Three Recent Independent Analyst Reports Nymox NicAlert™ Saliva Data to be Presented at International Meeting of Nicotine and Tobacco Experts Nymox Obtains CE Mark for NicAlert™; Product Now Available in Europe Nymox NX-1207 Pivotal Trial Gets Positive Efficacy and Safety Recommendation from Independent Data Monitoring Committee Nymox AlzheimAlert™ Findings To Be Presented at National Meeting Annual Symposium of the American Medical Directors Association Studies Show Nymox's AlzheimAlert™ Test Useful in Earliest Stage of Alzheimer's Disease E. Coli Contamination a World-Wide Public Health Threat Nymox Reports Completed Successful Studies of Saliva Test Nymox Signs New U.K. Deal for NicAlert™ Product Nymox Provides Update on Progress of the Company's Current Drug Trial of NX-1207 for Benign Prostatic Hyperplasia WallStreet Research Updates Coverage of Nymox Pharmaceutical Corporation Shares with Speculative Buy Recommendation at www.WallStreetResearch.org Statin Drugs May Help Reduce Alzheimer's Disease Risk in Many Ways, According to Expert Nymox Signs U.K. Deal for TobacAlert™ Second-Hand Smoke Test Nymox Receives Buy Recommendation with New Update by Cohen Independent Research Group Nymox Reports Updated Interim Safety Results in Pivotal Trial of New Drug For Benign Prostatic Hyperplasia New Lancet Article Points to Role for Cholesterol and Statin Drugs in Alzheimer's Disease CDC Researchers Find New Use for Nymox's NicAlert™ Product New Cardiovascular Studies Show Harm From Very Brief Exposure to Second Hand Smoke New Study Finds Additional Evidence that Statin Drugs May Help Slow Mental Decline in the Elderly Statins May Slow the Effects of Alzheimer's Disease According to New Study Nymox Reports Third Quarter 2005 Financial Results Medical Publication Highlights Positive Advances in Clinical Studies of Preventive Effects of Statin Drugs in Alzheimer's Disease Nymox Product Recommended in Today's London Daily Mirror New Study Finds that Second-Hand Smoke Exposure Doubles Lung Cancer Risk Nymox Files Further Proposals with FDA about Alzheimer Test Kit E. Coli Food Contamination of Beef a Threat World-Wide Nymox Announces $13 Million Equity Financing Nymox Smoking Test Products Receive Wide Media Coverage Nymox Signs New Marketing and Distribution Deal for NicAlert™ Test in Spain Nymox Reports Second Positive Interim Safety Results in Pivotal Trial of New Drug For Benign Prostatic Hyperplasia Nymox Adds European Sales Agreements For Company's Proprietary Unique AlzheimAlert™ Test Routine Screening for Second-Hand Smoke Exposure Recommended Nymox NXC-4720 Product in Late Stage Development for E. Coli O157:H7 Contamination Potential of Statins to Treat or Prevent Alzheimer's Disease Widely Recognized Nymox Continues to Successfully Expand Extensive Patent Portfolio Nymox NicAlert™ Featured in Nevada Tobacco Free Babies Project Presentation New Published Articles Support Mechanisms for Potential Use of Statins to Treat Alzheimer's Disease Update on Pivotal Trial of Nymox's NX-1207 For Benign Prostatic Hyperplasia Lancet Article Features Potential Use of Statins to Treat Alzheimer's Disease Nymox Signs Marketing Agreement With Brainpharma S. L. For AlzheimAlert™ Kit to Be Sold in Spain Second-Hand Smoke Kills as Many Women as Active Smoking in China According to New Study New Study Finds Early Life Second-Hand Smoke Exposure Can Produce Life-Long Respiratory Problems Second-Hand Smoke Costs $10 Billion A Year According to Insurance Study Second-Hand Smoke Takes its Toll Later in Life Nymox Reports Second Quarter 2005 Financial Results; Product Sales Increased by 63% over Second Quarter 2004 Nymox NicAlert™ Will be Used in Nevada Tobacco Free Babies Program Positive Interim Safety Results of Pivotal Trial of Nymox's NX-1207 For Benign Prostatic Hyperplasia Tobacco Smoke Exposure for Teens Linked to Obesity and Higher Risk of Cardiovascular Disease and Diabetes Second-Hand Smoke Exposure During Pregnancy Puts Fetus at Risk According to New Study Nymox Expands Its Issued Patent Position for E. Coli Treatments New Coverage of Nymox Initiated by Cohen Independent Research Group FDA Panel Votes 5-2 Against Kit Form of NTP Test Evidence and Acceptance Grows For Taking Statin Drugs to Treat Dementia Nymox Moves Forward With Global Marketing Agreements For Company's Proprietary AlzheimAlert™ Test Nymox NX-1207 For Benign Prostatic Hyperplasia Shows Promise For Common Problem Nymox Signs Marketing and Distribution Deal for AlzheimAlert™ Kit in Greece Exposure to Mother's Smoke Increases Risk of Asthma in Adults According to New Study Nymox Reports Positive New Data for BPH Drug Newly Published Studies Show Danger of Second Hand Smoke FDA Advisory Panel Meeting for Nymox PMA Application Expected in July 2005 Nymox and InnerLink Sign Agreement to Promote Nymox Tobacco Exposure Products Another Large New Published Study Shows that Taking a Statin Drug Reduces the Risk of Dementia Nymox Reports First Quarter 2005 Financial Results Standard & Poor's Stock Reports Gives Nymox “Bullish” Rating New Study Finds Evidence that Taking a Statin Drug Can Help Treat Alzheimer's Disease Statin Drugs Offer Positive New Pharmaceutical Approach to Alzheimer's Disease Treatment and Prevention Second-Hand Smoke Exposure a Key Topic at National Conference on Tobacco or Health Nymox Product Recommended in Today's N.Y. Daily News Nymox PMA Slated for FDA Advisory Panel Meeting Nymox Signs Marketing and Distribution Deal for Alzheimer's Disease Test with KlinLab in Czech Republic Nymox NicAlert™ Successfully Used as Clinical Tool for Expectant Mothers in Nevada Deadly E. Coli Bacteria Remains an Important Threat to U.S. Health According to New Study Newly Published Study Shows Growing Medical Acceptance of Statin Drug Usefulness in Treatment of Dementia New Medicare Decision to Cover Smoking Cessation Good News for Nymox Nymox Makes Major Progress in Global Marketing of Company's Proprietary Alzheimer Test Nymox Drug For Benign Prostatic Hyperplasia Holds Promise For Highly Prevalent Problem Two New Studies Document Dangers of Second Hand Smoke and Fetal Exposure to Maternal Smoking European Studies Show That Nymox's NicAlert™ Product Improves Smoking Cessation Nymox Reports 2004 Financial Results New Reports and Studies Highlight Importance of Alzheimer's Disease Diagnosis Breast Cancer Linked to Second Hand Smoke in New Report Nymox NicAlert™ Product Can Help Smoking Cessation Insulin Abnormalities Linked to Alzheimer's Disease by Researchers Effective Measures Needed to Reduce Tobacco's Deadly Toll Studies Show that Nymox NXC-4720 Product Can Substantially Reduce E. Coli Meat Contamination Nymox Expands Large Patent Portfolio Nymox Signs Italian Distribution Deal for Alzheimer's Disease Test with Alifax S.p.A. Nymox's Alzheimer Urine Test Now Available as Kit in Europe Childhood Exposure to Second Hand Smoke Increases Lung Cancer Risk for Adults According to New Study Second Hand Smoke Adversely Affects Children's Reading Scores, Math Skills and Reasoning Abilities Nymox Files Data with FDA for Alzheimer Urine Test Nymox Pharmaceutical Rated “Bullish” by Standard & Poor's Stock Reports Alzheimer's Disease Identified as a Priority for Europe in World Health Organization Study Nymox Reports Third Quarter 2004 Financial Results Taking Statin Slowed Progression of Alzheimer's Disease According to New Study Nymox Obtains CE Mark for AlzheimAlert™ Test Kit; Product Now Available in Europe Nymox Files PMA Amendment with FDA for Alzheimer Urine Test Statin Drugs and Mechanism for Alzheimer's Explored in Large Group of New Scientific Studies Nymox Issued U.S. Patent for Saliva Cholesterol Test Nymox TobacAlert™ To Be Available at CVS Pharmacies Across the U.S. Nymox Announces $13 Million Equity Financing Nymox Signs Licensing Agreement with Health Canada Nymox's TobacAlert™: A Simple, Cost-Effective Way of Measuring Second Hand Smoke Nymox Makes Steady Progress With Alzheimer's Products Nymox Develops New Methods of Treating Deadly E. Coli Food Contamination Nymox Files 6K Re Insider Stock Purchases Statin Drugs For Alzheimer's Recognized as Emerging Indication Nymox Successfully Expands Growing Patented Product Pipeline Nymox has Good News for National Prostate Health Month Statins Offer Hope for Alzheimer's Prevention Nymox Announces Positive One Year Prostate Drug Trial Results Nymox Reports Second Quarter 2004 Financial Results Nymox Announces Positive Settlements of Outstanding Litigation Nymox Advances Site Selection for New Prostate Trial Capital Growth Financial Reiterates “Buy” Recommendation of Nymox Nymox Reports Current Status of NTP Kit PMA Nymox Develops Treatment of Deadly E. Coli Food Contamination Nymox Releases Further Positive Data on U.S. Clinical Trials of NX-1207 in Men with Statin Drugs Attract Wide Attention For Alzheimer's Prevention Clinical Study Shows New Use for Nymox AlzheimAlert™ Test New Drug Trial Protocol Approved for Nymox Prostate Drug Nymox Rated “Bullish” by Standard & Poor's Stock Reports Nymox Pursuing New Approaches to Fighting Alzheimer's Disease Nymox's Tobacco Exposure Products Pass the Test in Australia Nymox AD Protein Marker Linked to New Cell Death Mechanism in Alzheimer's Disease Nymox Releases Positive Data on U.S. Clinical Trials of NX-1207 in Men with Benign Prostatic Hyperplasia -BPH- Nymox Gives Update Before Company's Annual General Meeting Nymox Reports First Quarter 2004 Financial Results CGF Securities Reiterates “Buy” Recommendation of Nymox with $9.00 Price Target Another Distinct Major New Study Confirms the Benefits of Statins in Reducing Risk of Alzheimer's Disease Large New Study Supports Statins For Alzheimer's Disease Nymox Alzheimer Urine Test Premarket Approval -PMA- Application Suitable for Filing Spheron Discovery Leads Nymox Alzheimer Developments Nymox Gains U.S. Patent For Saliva Cholesterol Test Future Value of Statin Drugs for Alzheimer's Quickly Growing According to Nymox Large New Study Shows Statins Boost Cognition in the Elderly Statin Drugs Reduce Alzheimer's Risk According to Studies Nymox Reports 2003 Financial Results Nymox Reports Progress in NXC-4720 E. Coli Product Nymox Alzheimer Biomarker Bolstered by New Findings in Journal of Alzheimer's Disease Nymox Shares Rated “Buy” in New Analyst Report New Study Finds a 39% Reduction in Alzheimer's Disease in Patients Taking Statin Drugs Nymox Files Premarket Approval Application with FDA for Alzheimer Urine Test Nymox's TobacAlert™ Product Attracts World-Wide Attention Drugs Reducing Cholesterol May Lower Risk of Alzheimer's Disease According to Recent Studies Six Independent Analyst Reports Recommend Nymox New Trial Results of Nymox NX-1207 Show Significant Clinical Improvement in Men with Benign Prostatic Hyperplasia –BPH– Nymox Rated “Buy” in New Analyst Report From TNI Securities New Study Shows Importance of Nymox AlzheimAlert™ Protein to Alzheimer's Disease Five Independent Analyst Reports Recommend Nymox New Study Confirms Nymox NXC-4720 Product Effective Against E. Coli Nymox Pharmaceutical Rated “Bullish” by Standard & Poor's Stock Reports Four Independent Analyst Reports Recommend Nymox Nymox Rated “Buy” in Initial Coverage Report by CGF Securities Nymox Shares Rated a Buy in Analyst Report Nymox Reports Third Quarter Results Nymox Will File Premarket Approval Application – PMA – with FDA for Alzheimer Urine Test Wallstreet Research Updates Coverage of Nymox Pharmaceutical Corporation Three Current Analyst Reports Recommend Nymox Nymox Pharmaceutical Corporation: Second-Hand Smoke Exposure High On The Public Agenda Across The U.S. Nymox Advances in the Treatment of Deadly E. coli Food Contamination Nymox Shares Rated a Buy in Analyst Report Nymox Adds New Drug Candidate for Neurodegenerative Disease to Product Pipeline Early and Accurate Diagnosis of Alzheimer's Disease High Priority for the Health Care System According to Nymox New Clinical Studies Show High Accuracy of Nymox's TobacAlert™ Statin Drugs Offer Hope for Meeting the Challenge of Alzheimer's Disease New Clinical Data Strengthens Nymox AlzheimAlert™ Product New Spheron Discovery Bolsters Nymox's Alzheimer Therapeutic Pipeline Smoking Cessation Programs Reduce Healthcare Costs for Employers Nymox Targets AlzheimAlert™ Product for the Global Market Nymox Management Announces Up to Four New Investigational Drugs Nymox Reports New Positive Studies of AlzheimAlert™ Product Nymox New TobacAlert™ Product Now Available at CVS Pharmacies Nymox Introduces New TobacAlert™ Product Nymox Announces $12 Million Additional Financing New Analyst Report Recommends Nymox Shares Recent Surveys Show Nymox Products Widely Featured on Television in U.S. and Abroad Alzheimer's Disease Rising Prevalence Will Challenge Health Care System Nymox Reports Positive NXC-4720 E. Coli Product Data Nymox Reports Positive Data on AlzheimAlert™ Product Nymox Records Positive Interim Results in Phase I Testing of NX-1207 Prostate Drug Nymox Reports Second Quarter Results Nymox Announces E. Coli Collaboration for Research with Health Canada New Survey Results Show That Few Young Women Smokers Able to Quit Nymox Brings Unique Approach to Alzheimer's Disease Antimicrobial Products Needed to Combat E. Coli Contamination Recent Studies Support Potential for Statin Drug Use in Alzheimer's Disease Nymox Recommended in Three Recent Independent Analyst Reports Statin Drugs and Their Promise Against Alzheimer's Disease Featured in Cover Story of Newsweek Magazine Employee Benefit Programs in U.S. Increase Coverage of Smoking Cessation Programs Beef Recall Highlights Need for E. Coli Treatment Nymox Products Widely Featured on U.S. Television Dutton & Associates Reiterate "Buy" Recommendation for Nymox Pharmaceutical Corporation Alzheimer's Disease Highlighted as Potential New Indication for Statin Drugs American Respiratory Alliance Will Use Nymox's NicAlert™ as its Official Test Agent in Smoking Cessation Programs Nymox Pharmaceutical Corporation Recommended in Three Current Independent Analyst Reports Nymox Rated "Speculative Buy" By New WallStreet Research Report Nymox Management Projection of Up to Four New INDs in the Next 12 Months Nymox Pharmaceutical Corporation Recommended in Two Independent Analyst Reports Nymox Rated "Buy" By Kareg Corporation Analyst Nymox Innovative Alzheimer Drug Programs Report Progress Nymox Reports Progress in Oncology Collaboration With Brown University Medical Researchers Nymox NicAlert™ Product Used Successfully in European Broadcast TV Smoking Cessation Program Nymox NicAlert™ Product Used to Help High School Students Quit Smoking Nymox Reports Positive Alzheimer Drug Candidate Research Task Force Report Highlights Need for Accurate Diagnosis of Alzheimer's Disease Smoking During Pregnancy Affects Newborn Behavior According to New Study European Clinical Trial Shows Nymox NicAlert™ Product Can Help Smokers Quit Nymox Reports NXC-4720 E. Coli Product Update Nymox Reports Positive New Data on AlzheimAlert™ Product Recent Studies Support Statin Drug Treatment Potential in Alzheimer's Disease Nymox Scientists Uncover Major New Molecular Clue to Alzheimer's Disease Swiss Study Shows Nymox's NicAlert™ Helps in Smoking Cessation Therapy Nymox's NicAlert™ Used in Conjunction With Nicotine Replacement Therapy Results in Higher Smoking Cessation Success Rates Alzheimer's Disease Poses Major Challenge to Health Care System According to Experts Fourth Manhattan Alzheimer's Disease Conference, sponsored by Nymox Pharmaceutical Corp., to be Held in New York on May 27 Nymox "Buy" Recommendation from Dutton & Associates Nymox Reports First Quarter Results Nymox AlzheimAlert™ Urine Test Useful to Monitor Alzheimer Treatment According to New Studies Nymox's NicAlert™ Checks for Winners in Quit Smoking Contest New Study Supports Statin Drugs Potential in Alzheimer Patients Availability of AD Treatments Increases the Value of Nymox's AlzheimAlert™ Nymox E. Coli Treatment Targets a Pressing Need Nymox Appoints New Senior Manager for Global Sales and Marketing Fourth Manhattan Alzheimer's Disease Conference on May 27 Sponsored by Nymox Will Feature World Class Assembly of Speakers and Panelists Nymox's NicAlert™ Can Detect Second-Hand Smoke Exposure in the Home Nymox Reports Positive Results for NXC-4720 E. Coli Treatment Statin Drug Treatment for Alzheimer's Supported by New Findings Nymox Reports 2002 Financial Results Dutton and Associates Initiates Coverage of Nymox With a "Buy" Recommendation Nymox's NicAlert™: A Valuable Tool for Smoking Cessation Programs Nymox Announces New Successes with Diagnostic Platform New Second Hand Smoke Trial Results Confirm Usefulness and Accuracy of Nymox's NicAlert™ Nymox Announces $5 Million Additional Financing Excellent Results for Nymox's NicAlert™ Presented at National Meeting Nymox Begins Phase I Human Studies for NX-1207 Prostate Treatment Nymox Develops New AlzheimAlert™ Test Kit for Overseas Markets Statin Drug Treatment Potential For Alzheimer's Bolstered By New Studies Nymox's NicAlert™ Can Determine Smoke Exposure in High Risk Patients in the Clinic Nymox's NicAlert™ Successfully Used By High School Students in Switzerland Nymox Announces Private Placement New Public Health Importance For Nymox's NicAlert™ Nymox Rated "Buy" In New Analyst Report from WallStreet Research Nymox's AlzheimAlert™ Can Help in the Early Diagnosis of Alzheimer's Disease Nymox Pharmaceutical Rated "Bullish" by Standard & Poor's Stock Reports New Markets Open for Nymox's NicAlert™ Nymox's NicAlert™ Helps Physicians Determine Tobacco Smoke Exposure and Smoking Status of Their Patients Nymox U.S. Patent Issued For Statin Drugs For Alzheimer's Disease Nymox Enters into New Sales Agreement for NicAlert™ in Japan FDA Clears Nymox's NicAlert™ Important New Publication Adds Prestige to Nymox Product New Published Independent Study Finds Nymox Product to Be a Rapid and Cost-Effective Measure of Smoking Status New Progress With Nymox's AlzheimAlert™ Product Nymox Successfully Expands Growing Product Pipeline Nymox Reports Alzheimer Drug Progress Nymox Announces Private Placement Nymox NicAlert™ Used in Major Lung Center in Zurich, Switzerland Nymox NicAlert™ Used in National Stop-Smoking Campaign in Switzerland New Nymox AlzheimAlert™ Study Begins in Phoenix Nymox Announces New Marketing Initiatives With Health4u in Switzerland Nymox Begins New NicAlert™ Study For Second-Hand Smoke Nymox Leads with Innovative Alzheimer's Disease Programs New Nymox AlzheimAlert™ Study at State University of New York New Nymox Second-Hand Smoke Study Begins for NicAlert™ Second-Hand Smoke Implicated in Heart Disease and Stroke Nymox NicAlert™ Test Valuable In Employee Tobacco Cessation Programs Nymox Announces Private Placement New Evidence Supports the Use of Statins for the Prevention and Treatment of Alzheimer's Disease Nymox's AlzheimAlert™ To Be Presented at the Annual Meeting of the American Association for Clinical Chemistry Nymox Gains U.S. Patent for Use of Statins for Prevention and Treatment of Alzheimer's Disease Significant New Evidence Links Nymox's AlzheimAlert™ Protein to Alzheimer's Disease Process Nymox Pharmaceutical Corporation Featured in The Wall Street Transcript Nymox Files Investigational New Drug, IND, Application with FDA for Prostate Drug Candidate NX-1207 World Health Organization Links Second Hand Smoke to Cancer Nymox Announces Progress with Drug Candidate for Alzheimer Treatment Nymox Pharmaceutical Rated "Bullish" by Standard & Poor's Stock Reports Nymox Plans to File Investigational New Drug-IND-Application with FDA for Prostate Drug Candidate NX1207 Nymox Submits 510k Application to FDA For NicAlert™ Test New Study on Teen Smoking Shows How Easily Smoking Leads to Nicotine Dependence Nymox Presents Positive AlzheimAlert™ Results at Annual Meeting of American Geriatrics Society Nymox Pharmaceutical Shares Upgraded to "Buy" Recommendation by WallStreet Research Nymox's NicAlert™ Can Help Smokers Quit Successful New Clinical Study of Nymox's AlzheimAlert™ Test Reported in Alzheimer's Reports New Positive Results for Nymox's AlzheimAlert to be Presented at National Meeting Nymox Obtains Cancer Marker Licensing Agreement from Massachusetts General Hospital Nymox More Than Doubles 2001 Revenues and Announces Significant Improvement in Results Nymox Announces New Cancer Therapeutic Program with Brown University Nymox's NicAlert Potential Aid in Second-Hand Smoke Child Custody Cases Nymox Announces Private Placement Medicare's Decision to Cover Treatment for Alzheimer's Disease Will Positively Impact on Nymox's AlzheimAlert™ Nymox AlzheimAlert™ Featured on Good Housekeeping Medical Report Broadcast Nymox Reports Continued Progress with Prostate Drug Candidate NX1207 Nymox Selected For BusinessWeek Equity Investor's Micro-Cap Review Nymox's AlzheimAlert™ Test to be Used in Tufts University Study on Alzheimer's Disease New Study Shows Nymox NicAlert™ Product Detects Second-Hand Smoke in Children Nymox Develops New Alzheimer Drug Candidate Nymox Announces Private Placement Nymox Adds New Online Marketing Initiatives Large National Study Supports Nymox's Emerging AlzheimAlert Diagnostic Technology Nymox Announces New Research and Licensing Agreement With Brown University Nymox Pharmaceutical Shares Recommended by WallStreet Research at www.WallStreetResearch.org Nymox AlzheimAlert™ Story to be Internationally Televised in 200 Cities and 127 Countries Worldwide Online Publication of Successful Clinical Study of Nymox's AlzheimAlert™ Test Nymox Management and Directors to Purchase Up to One Million Nymox Shares Nymox's AlzheimAlert™ Test Featured as Useful Biomarker for Alzheimer's Disease in Current Issue of Clinical Laboratory International Nymox Alzheimer's Research Leads to Promising Prostate Drugs Company Plans to File Investigational New Drug Application for Benign Prostatic Hyperplasia in 2002 Nymox AlzheimAlert™ Urine Test Shows Promise to Monitor Alzheimer Treatment and Progression According to New Study Third Manhattan Alzheimer's Disease Conference, Sponsored by Nymox Pharmaceutical Corp., to be Held in New York on November 28 Nymox's AlzheimAlert™ To Be Presented at the Annual Meeting of the Society for Neuroscience Nymox Technology Highlighted in Science Magazine Nymox NicAlert™ Test Recommended by Tobacco Researchers Nymox Enters Strategic Marketing Alliance with Cybear, a Member of the Andrx Corporation Nymox Website Highly Rated in Web Exposure Report Nymox Pharmaceutical Corp. to Hold Third Manhattan Alzheimer Disease Conference in November 2001 Nymox's AlzheimAlert™ Test Featured in Current Issues of Nursing and Radiology Periodicals Nymox Pharmaceutical Corporation Makes Donation for the Victims of September 11, 2001 Nymox Appoints Dr. Paul A. Kraus as Clinical Consultant Nymox's AlzheimAlert™ To Be Featured Topic on National Radio Show Nymox NicAlert™ Test Slated for Large Second-Hand Smoke Study Nymox Pharmaceutical Rated "Bullish" by Standard & Poor's Stock Reports Nymox E. Coli Treatment NXC 4720 Shows Encouraging Results Nymox Enters into Korean Distribution Agreement for NicAlert™ Importance of Nymox AlzheimAlert™ Test Emphasized in Anti-Aging Medical Therapeutics Chapter Nymox AlzheimAlert™ Used by Legal Experts in Forensic Cases Nymox AlzheimAlert™ Protein "An Excellent Biomarker" for Alzheimer's Disease According to New Scientific Publication Nymox Reports Successful AlzheimAlert™ Clinical Study Published in Neurology & Clinical Neurophysiology Importance of Nymox AlzheimAlert™ Test Emphasized in New Publication in the Journal of Longevity Nymox AlzheimAlert™ Test Featured in New Article in ADVANCE Laboratory Publication Nymox Scientists Report Positive Clinical Trial Data for AlzheimAlert™ Test at World Congress of Neurology Nymox Scientists Discover Important New Family of Therapeutic Compounds Nymox Pharmaceutical Corporation Featured in The Wall Street Transcript AMA Briefing Strongly Confirms the Importance of the Early Diagnosis of Alzheimer's Disease Nymox AlzheimAlert™: "A Leap Forward in Early Detection" New Medical Publication Links Nymox AlzheimAlert™ Protein with Alzheimer's Disease Nymox Alzheimer Drug Programs Featured in Current Drug Discovery Positive New Laboratory Studies for Nymox Alzheimer's Disease Drug Candidate Nymox's AlzheimAlert™ Test Further Supported by New Medical Publications Nymox Expands E. Coli Product Development New Clinical Trial Publication Supports Nymox's AlzheimAlert™ Test Nymox Adds Significant Value to Global Patent Holdings Large New Community Study Proves Usefulness of Nymox's AlzheimAlert™ Test Importance of Spherons in Alzheimer's Disease Highlighted by New Study Nymox's NicAlert™ Measures Best Biomarker for Tobacco Use and Exposure Nymox Announces Appointment of Scientific Consultants, Dr. Thomas Hudson and Dr. Joe Dylewski Nymox Developing New Drug Candidates for the Treatment of Alzheimer's Disease Experts Recommend Nymox's NicAlert™ Test New Clinical Trial Data Supports Nymox's AlzheimAlert™ Test New Study Confirms Again the Reliability and Efficacy of Nymox's AlzheimAlert™ Test Prestigious Publication Confirms the Significance of Nymox's Alzheimer's Disease Marker Nymox's AlzheimAlert™ Test Gaining Recognition and Wide Medical Acceptance Nymox Announces E. Coli Collaboration with Prestigious Veterinary Institution Nymox and Biophage to Co-Develop Antimicrobial Treatments Nymox's E. Coli Inhibitor Effective in Independent Tests Nymox Launches New Internet Presence Nymox Management and Board of Directors Announce Share Purchase Nymox Announces New Alzheimer Drug Screening Developments Nymox to be Featured on American Medical Review Nymox Presents AlzheimAlert™ Test at Annual Meeting of American Academy of Anti-Aging Nymox Presents Positive Clinical Trial Data at Meeting of American Psychiatric Association New Scientific Publication on Nymox Alzheimer Test Nymox Alzheimer Test Recommended in Anti-Aging Medical News Nymox Announces Launch of New AlzheimAlert™ Test Nymox Appoints Robert Rush Ph.D. D.A.B.C.C. as New Clinical Laboratory Director for Alzheimer's Diagnostic Aid Nymox Announces Marketing Launch with New Sales Force for Alzheimer Aid to Diagnosis Nymox-Serex's Nicotine Test Shown to be Useful in Pediatric Second Hand Smoke Studies Nymox Appoints Suzanna Levy Ph.D. as Clinical Laboratory Scientific Director for Alzheimer's Diagnostic Aid Nymox's Product Portfolio Well-Positioned to Provide Diagnostic Testing for Aging Baby Boomers World's First Direct Visualization of Bursting Spherons in Alzheimer's Disease Reported at Manhattan Alzheimer's Conference Nymox Announces Positive Clinical Trial Result in 7C Gold Urinary Study in Alzheimer's Disease New Confirmatory Findings on Spherons in Alzheimer's Disease Presented at International Congress of Neuropathology New Publication Confirms Major Significance of Spherons in Alzheimer's Disease First Urinary Diagnostic Aid by Nymox Proven to be Accurate by New Peer Reviewed Publication Nymox Announces Agreement between Serex Inc. and Mizuho Medy Co. Ltd. in Japan Nymox Announces Development of New Kit to Aid Alzheimer's Diagnosis Nymox Announces New Member of the Board, Professor Walter P. von Wartburg New Publication of Peer-Reviewed Study in Neurology Independently Verifies Nymox AD7C™ Test Nymox Announces New Member of the Board, Michael R. Sonnenreich Nymox's AD7C Test Found to be Highly Attractive and Useful in New Journal Publication Nymox Completes Private Placement of $4.0 Million Nymox Finalizes Acquisition of Majority Interest in Serex, Inc. Two Recently Published Books Cite Value of Nymox's AD7C™ Test As Aid in Early Detection and Diagnosis of Alzheimer's Disease Co-Founders of American Academy of Anti-Aging Medicine Laud Value of Nymox's Alzheimer's Developments Diagnosing Memory Loss Nymox Gaining Recognition as Scientific Advances Continue Nymox Scientists Find Additional Evidence That Spherons Are Cause of Alzheimer's Disease Nymox's New E. Coli Treatment Shows Promising Results Nymox to Trade Exclusively on Nasdaq Nymox Raises $12 Million in Financing Commitment Nymox Pharmaceutical and Loyola Scientist Announce Link Between Statin Drugs and Lowered Rate of Alzheimer's Disease Studies Validate New Nymox Alzheimer's Test; Nymox Reports Successful Completion of Initial Key Validation Studies for its New "7C Gold" Alzheimer's Disease Test Clinical Laboratory News Terms Nymox's AD7C™ Test Clinical Trials Confirms Accuracy of Nymox's AD7C™ Alzheimer Test, According to Paper Presented at American Assn. for Clinical Chemistry Nymox Announces Breakthrough Development in Alzheimer Testing Nymox Announces New Member of the Board Hans Black, M.D. Nymox's Alzheimer Test Shown to have Expanded Clinical Usefulness Human Testing Next Step for Nymox's Revolutionary Alzheimer Drugs Nymox Announces Further Independent Clinical Study Data Verification of its AD7C™-NTP Alzheimer Testing Technology Nymox Reports Positive Progress in Spheron Based Drugs for Alzheimer's Disease Studies at International Symposium Support Nymox Alzheimer Test notify me about updates	Nymox's NicAlert™ Used in Conjunction With Nicotine Replacement Therapy Results in Higher Smoking Cessation Success Rates MAYWOOD, NJ (May 22, 2003) Nymox Pharmaceutical Corporation's (NASDAQ: NYMX) NicAlert™ is "easy to use, cost-effective and accurate," according to a team of Swiss researchers led by Dr. Karl Klingler of the Hirslanden Lung Center, Zurich, Switzerland. The researchers recently presented their findings to the Assembly of Pneumologists in St.Gallen, Switzerland. The Swiss researchers conducted a study to evaluate the use of NicAlert™ in conjunction with nicotine replacement therapy (NRT) in smoking cessation and reduction programs. The initial study was successful . NicAlert™ use led to higher success rates for smoking cessation. NicAlert™ is now being used to help tailor initial NRT dosages for subjects and to evaluate progress in a randomized smoking cessation trial. "The success rates of smoking cessation with nicotine replacement therapy have historically been low (about 15%). NicAlert™ provides a quick, easy and accurate way of measuring a person's level of nicotine exposure on-site. The results of this pilot study indicate how NicAlert™'s unique proprietary technology offers physicians and smokers the ability to individualize the appropriate level of nicotine replacement for successful smoking cessation," said Dr. Michael Munzar, Medical Director of Nymox. NicAlert™ received clearance from the U.S. FDA in October 2002. NicAlert™ was recently used by the Quebec Public Health Department of Nunavik in Canada to check the current smoking status of potential winners of a 2003 Regional Quit to Win Challenge. NicAlert™ was also used in a nationwide stop-smoking campaign jointly run by the Swiss Federal Office of Public Health, the Swiss Association for Smoking Prevention, the Swiss League Against Cancer and the Swiss Lung Association. NicAlert™ was also recently successfully used in Switzerland in high school students in an awareness campaign in Basel. NicAlert™ is a powerful one-step patented urine test for detecting smoking and tobacco product exposure that combines the advantages of semi-quantitative measurement together with an easy-to-use, cost effective, rapid format. NicAlert™ does not require any instruments or special training for its use. Two recent independent peer-reviewed studies found the technology employed in NicAlert™ to be an accurate, rapid and cost-effective means of confirming smoking status. One study, "Validating a Dipstick Method for Detecting Recent Smoking," Cancer Epidemiology, Biomarkers & Prevention (2002; 11: 1123-1125) was authored by Peter Gariti of the University of Pennsylvania Cancer Center Group, Philadelphia Veterans Affairs Medical Center and the University of Pennsylvania School of Medicine, David I. Rosenthal of the M.D. Anderson Cancer Center in Houston, Kathleen Lindell of the University of Pittsburgh and John Hansen-Flaschen, Joseph Shrager, Craig Lipkin, Arthur I. Alterman and Lawrence R. Kaiser of the University of Pennsylvania School of Medicine. The study examined the smoking status of patients at a cancer clinic and found that the results obtained using Nymox's tobacco product exposure test had an "excellent agreement" with state-of-the-art sophisticated laboratory measurements but at a substantially lower cost (over 90% less). The second study, "The Accuracy of Self-Reported Smoking Status Assessed by Cotinine Test Strips," Nicotine & Tobacco Research (2002; 4: 305-9) was authored by Donna R. Parker, ScD, and Thomas M Lasater, PhD, Brown University School of Medicine; Richard Windsor, PhD, MPH, George Washington University Medical Center; Jeff Wilkins, MD, Greater Los Angeles VA Healthcare Center, David Upegui, BA, Memorial Hospital of Rhode Island; and James Heimdal, PhD, The Hoffman Heart Institute, Saint Francis Hospital and Medical Center, Hartford, CT. The study found Nymox's product to be "an inexpensive and rapid method to routinely biochemically confirm smoking status at a clinical visit." The authors described the Nymox product as a "simple, inexpensive and rapid measure to immediately confirm smoking status in field settings." The U.S. Surgeon General, the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and many other public health organizations have targeted tobacco use as the single most preventable cause of premature death today. The CDC estimates that smoking causes over 440,000 premature deaths annually in the United States and creates an economic loss of over $150 billion a year. More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. Want more information? Click here! Email this page to a friend or colleague Show a printer-friendly version of this page